SER · Serina Therapeutics, Inc.
$2.07
-0.02 (-0.96%)
At close · Jul 24
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations within one year of the unaudited condensed consolidated interim financial statements issuance date, raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$31.04M
Shares
15.00M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$130K
+132.1%
FY2025
Net Income
-$19.18M
-72.2%
FY2025
Gross Margin
3.24%
-58.5pp
FY2023
Operating Margin
-18478.46%
+11964.4pp
FY2025
Diluted EPS
-$1.91
-26.5%
FY2025
Operating Cash Flow
-$17.96M
-4.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | $130K | $56K | $3.15M | $34K | $144K | $361K | $1.73M | $1.4M | $1.4M | |
| — | — | — | $40K | $13K | $19K | $26K | $244K | $364K | $168K | |
| — | — | — | $102K | $21K | $125K | $335K | $1.48M | $1.03M | $1.24M | |
| — | — | — | 3.24% | 61.76% | 86.81% | 92.8% | 85.88% | 73.93% | 88.03% | |
| $13.4M | $13.16M | $7.48M | $2.39M | $1.03M | $1.46M | $3.71M | $5.9M | $5.83M | $5.78M | |
| $11.17M | $11M | $9.62M | $3.89M | $5.97M | $6.71M | $6.72M | $8.14M | $5.65M | $3.87M | |
| — | — | $100K | $131K | $132K | $131K | $132K | $558K | $477K | $517K | |
| — | $100K | $100K | $90K | — | — | $699K | $393K | $58K | — | |
| — | — | — | — | — | $195K | $195K | — | — | — | |
| $24.57M | $24.15M | $17.1M | $6.28M | $7M | $8.16M | $10.44M | $14.04M | -$12.28M | $9.65M | |
| — | -$24.02M | -$17.05M | -$3.13M | -$6.98M | -$7.93M | -$10.1M | -$12.56M | -$11.25M | -$6.66M | |
| — | -18478.46% | -30442.86% | -99.24% | -20514.71% | -5509.03% | -2797.78% | -726.79% | -805.52% | -474.57% | |
| — | -$23.92M | -$16.95M | -$3.04M | — | — | -$9.4M | -$12.17M | -$11.19M | — | |
| $402K | $213K | $526K | $4.9M | $3.34M | $1.1M | — | — | — | — | |
| $3.18M | $4.83M | $5.84M | $8.4M | -$3.55M | -$649K | -$299K | $323K | $3.51M | $26K | |
| — | -$19.2M | -$11.21M | $5.27M | $10.5M | $8.7M | -$11.13M | -$12.24M | -$7.73M | — | |
| — | $18K | $0 | $0 | — | — | -$150K | $148K | — | — | |
| -$6.9M | -$19.18M | -$11.14M | $5.27M | -$10.46M | -$8.68M | -$10.87M | -$12.15M | -$7.5M | -$6.58M | |
| — | -14755.38% | -19894.64% | 167.11% | -30770.59% | -6024.31% | -3009.7% | -703.36% | -537.39% | -468.66% | |
| -$24K | -$33K | -$66K | $0 | -$60K | -$3000 | -$111K | -$230K | -$229K | -$57K | |
| -$21.56M | -$19.44M | -$11.14M | $5.27M | — | $8.58M | $10.39M | — | — | — | |
| — | -$19.2M | -$11.14M | — | -$10.52M | -$8.83M | -$10.9M | -$12.31M | -$7.8M | $6.63M | |
| USD/shares | — | -$1.91 | -$1.51 | $2.36 | -$9.70 | -$8.21 | — | — | — | — |
| USD/shares | — | -$1.91 | -$1.51 | $0.73 | -$9.70 | — | — | — | — | — |
| shares | — | 10.19M | 7.36M | 2.24M | 1079 | 1.06M | 1.05M | 1.04M | 977.59K | 858.03K |
| shares | — | 10.19M | 7.36M | 7.35M | 1079 | 1.06M | 1.05M | 1.04M | 977.59K | 858.03K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $130,000 | $56,000 | — |
| Reportable Segment | — | — | $3,153,000 |
By Geography (USD)
| Component | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| United States | $90,000 | $10,000 | $107,000 | $323,000 |
| Foreign | $52,000 | $24,000 | $37,000 | $38,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Grant Revenues | $130,000 | $56,000 | — | — | — | — |
| Grant Revenues | — | — | $153,000 | — | $104,000 | $307,000 |
| License Revenue | — | — | $3,000,000 | — | — | — |
| Other Revenues | — | — | — | $34,000 | $40,000 | $54,000 |
| Subscription and Advertisement Revenues | — | — | — | — | $300,000 | $1,300,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$24,022,000 | -$17,048,000 | — |
| Reportable Segment | — | — | -$3,129,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -18478.5% | -30442.9% | — |
| Reportable Segment | — | — | -99.2% |